Home / Industry News / U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease


The U.S. Food and Drug Administration (FDA) has approved VYNDAQEL® (tafamidis meglumine) and VYNDAMAXTM (tafamidis) for use in adults with cardiomyopathy due to transthyretin amyloidosis.  More information can be found here.


Share This